A new animal model for studying muscular dystrophy, a mutant form of the nematode Caenorhabditis elegans, brings the power of worm genetics to bear on the search for a cure for this disease; work on this worm has already led to the identification of a novel component that can suppress the mutant phenotype.
The human genome project has generated great expectations for advancing our understanding of genetic diseases and developing cures. One of the first human genes identified using genomic technology was the dystrophin gene, which is defective in Duchenne and Becker muscular dystrophies [1] . Despite the enormous amount of information that we have gained about the function of dystrophin and its tightly associated protein complex, there is still, sadly, no cure for Duchenne muscular dystrophy. A number of animal models for Duchenne muscular dystrophy are available, but there is particular interest in a new model, a mutant form of the nematode worm Caenorhabditis elegans, reported by Segalat and colleagues [2] in a recent issue of Current Biology. This recent work raises hope that the fruits of the genome project might be combined with the power of C. elegans genetics to accelerate the search for a cure for Duchenne muscular dystrophy. Analyzing the function of muscle proteins in mouse and human systems can be slow and difficult, and the ability to study muscular dystrophy in C. elegans adds a new dimension to the field.
Genetic analysis in C. elegans is providing important insights into the assembly and function of muscle (reviewed in [3, 4] ). Because muscle structure and muscle proteins are highly conserved, much of what is learned from the nematode can be extrapolated to other animals, including man. The worm is a particularly attractive organism in which to study muscle. The usual self-fertilization allows propagation of muscle mutants that render animals so uncoordinated that they would be unable to mate. Large numbers of animals can be handled, thereby making screens for rare mutations, including extragenic suppressors or enhancers, practical. Many of the components of the myofibrils and their membrane-extracellular matrix attachment structures have been identified, primarily by first identifying mutants that are slow moving adults -the 'Unc' classor those that die as embryos with a characteristic phenotype -the 'Pat' class.
Until recently, most of what was known about the function of dystrophin came from studies in mice [5] . Dystrophin, and the closely related homolog utrophin, are cytoskeletal proteins that link the subsarcolemmal cytoskeleton to the extracellular matrix (Figure 1 ) [6] . The amino-terminal α-actinin-like domain of dystrophin and portions of the spectrin-repeat-containing rod domain bind actin, while the WW domain, the cysteine-rich region and the coiledcoil-containing carboxy-terminal domain bind a large complex known as the dystrophin glycoprotein complex. The dystrophin glycoprotein complex appears to be composed of at least two functionally distinct subcomplexes, one composed of the proteins dystroglycan, sarcoglycan and sarcospan, and the other of dystrobrevin and syntrophin.
Several additional proteins bind the dystrophin glycoprotein complex with lower affinity, including neuronal nitric oxide synthase (nNOS; Figure 1 ). As dystroglycan links dystrophin to the extracellular matrix by binding to laminin, it has been assumed that the dystrophin glycoprotein complex plays a mechanical role in protecting muscle cells from contraction-induced injury [7] . Nonetheless, several lines of evidence suggest that the syntrophin-dystrobrevin subcomplex may play a signaling, rather than a mechanical role, and it is possible that the sarcoglycans play both roles [8] [9] [10] . It has, however, proved difficult to further our understanding of these roles, and of the nature of the signals that might be transmitted, through experiments using mammalian models.
Interestingly, perusal of the C. elegans genome sequence in the WormPD database (Proteome, Inc.) reveals genes encoding homologs of many of the components of the mammalian dystrophin glycoprotein complex. These include genes for a homolog of γ-sarcoglycan (F07H5.2) and two syntrophin homologs (F27D9.8 and F30A10.8), and single copies of genes encoding proteins very similar to dystrophin (dys-1) [11] and dystrobrevin (dyb-1) [12] . There is also a predicted protein, T21B6.1, with weak similarity to human dystroglycan 1. A recent search for genes encoding homologs of known cytoskeletal proteins in the complete Drosophila genome [13] revealed single copies of genes coding for homologs of dystrophin (CG7240) and dystrobrevin (CG8529). Also, as is true of the worm, the fly apparently has two syntrophins (CG4905 and CG7151).
Thus, as first reported by Roberts and Bobrow [14] , invertebrates have a single gene for dystrophin, whereas humans have three, for dystrophin, utrophin and DRP2. It is inferred that duplication of the invertebrate dystrophin gene early in vertebrate evolution gave rise to DRP2 and a common ancestor of dystrophin and utrophin. Later, a second duplication of one of these genes resulted in separate dystrophin and utrophin genes. As reported by Bessou et al. [11] , the nematode dystrophin homolog has a very similar domain organization to human dystrophin.
The dystrophin gene in C. elegans was identified by forward genetics: Bessou et al. [11] isolated multiple loss-offunction mutations in the same gene, dys-1, that rendered the worms hyperactive. Subsequent molecular analysis revealed that dys-1 encodes the only dystrophin homolog in the worm. The dys-1 mutants are hyperactive, have exaggerated bending of the anterior part of their bodies, and have a tendency to hypercontract when moving backwards. The authors reasoned that the motility defects might result from increased cholinergic activity, so they tested dys-1 mutants for sensitivity to the drug aldicarb, which blocks acetylcholinesterase and thereby increases the levels of acetylcholine in the synaptic cleft. They found that dys-1 mutants are indeed significantly more sensitive to aldicarb than wild-type animals. They further confirmed that dys-1 mutants are hypersensitive to acetylcholine by measuring muscle membrane depolarization in response to increasing concentrations of acetylcholine.
Significantly, the muscle structure of dys-1 mutants was found to be normal, and there was no evidence of degeneration. Bessou et al. [11] investigated the expression pattern of dys-1 by linking the gene's probable regulatory sequences to a reporter coding for green fluorescent protein; the expression of this reporter construct in transgenic worms indicated that dys-1 is expressed only in muscle. Interestingly, these investigators were able to obtain partial rescue of the hyperactive phenotype of dys-1 mutants by expression of a transgene encoding the very amino-terminal 358 residues of the nematode protein and the carboxy-terminal half of the human protein.
In the conclusion of their paper, Bessou et al. [11] noted that "in C. elegans, four additional genes lead, when mutated, to a phenotype similar to that of the dys-1 mutants". One of these genes, dyb-1, was found by Segalat and colleagues [12] to encode dystrobrevin. C. elegans dystrobrevin is 38% identical in sequence to the human and mouse dystrobrevin α1 isoforms, and only lacks the phospho-tyrosine-containing tail that is present in several mammalian dystrobrevins. Furthermore, although mammalian dystrobrevins are specified by two genes encoding multiple isoforms, C. elegans contains just a single gene without evidence of alternative splicing. Because dyb-1 and dys-1 mutants have nearly identical behavioral and pharmacological phenotypes, it was argued that their protein products have similar physiological functions. Moreover, the phenotypes suggest that both proteins have a role in cholinergic signaling. Curiously, this is consistent with the original identification of dystrobrevin as a protein that copurified with nicotinic acetylcholine receptors from Torpedo postsynaptic preparations. In mammals, a specialized dystrophin glycoprotein complex, anchored by utrophin rather than dystrophin, contains specific isoforms of dystrobrevin and syntrophin and plays a role in acetylcholine receptor clustering [15] .
Segalat and colleagues [2] have now gone on to construct a double mutant C. elegans, carrying a combination of a dys-1 null mutation and a weak mutation in hlh-1, which encodes a homolog of the muscle-specific transcription factor MyoD. Remarkably, the dys-1(0); hlh-1(weak) animals show a timedependent loss of motility and egg-laying, and muscle degeneration. This is very similar to the observations on mouse mutants. Mice mutant for just the dystrophin gene mdx show only a mild myopathy; mice lacking both dystrophin and MyoD, however, show a severe myopathy [16] . Nevertheless, the two types of double mutant are not Structure of the mammalian dystrophin glycoprotein complex. Dystrophin/utrophin (Dys/Utr) is shown as an extended rod that binds actin and members of the dystrophin glycoprotein complex (most of the central rod domain is not shown). Dystroglycan (Dg) links to laminin in the extracellular matrix. In muscle, the dystrophin glycoprotein complex is located along the sarcolemma, while the related utrophin complex is located at neuromuscular and myotendinous junctions. At neuromuscular junctions, the utrophin complex helps organize large clusters of acetylcholine receptors (AChR), probably through an interaction with rapsyn (R). Dystroglycan at the neuromuscular junction can also bind agrin and perlecan. Other proteins shown are the sarcoglycans (Sg), sarcospan (Sp), syntrophins (Syn), dystrobrevins (Db), and nitric oxide syntase (NOS). The syntrophins have been shown to bind many different proteins, including several protein kinases (see [15] for a review). entirely analogous. In mice, the increased severity of the myoD; mdx phenotype is likely to result from a reduced ability of muscle to regenerate from 'satellite' stem cells. Nematode muscle, however, does not contain satellite cells. In C. elegans, muscle forms in the absence of MyoD, but it does not contract properly. The mild myoD mutation in this double mutant, by itself, has no obvious effect on muscle structure or function. It remains a mystery why muscle degenerates in dys-1; hlh-1 double mutant worms.
Segalat and colleagues [2] hope to use the double mutant worm to look for suppressors of the muscle degeneration, not only to identify new components of the dystrophin glycoprotein complex but also to identify potential targets for the therapy of Duchenne muscular dystrophy and Becker muscular dystrophy. As a proof of concept, they isolated a gene, dyc-1, mutations in which cause a hyperactive phenotype similar to dys-1 and dyb-1. The dyc-1 gene encodes a novel protein with two regions of homology to the mammalian nitric oxide synthetase binding protein CAPON, and is expressed in nematode muscles. More importantly, the authors found that, when dyc-1 is overexpressed, it partially suppresses the degeneration phenotype of the dys-1; hlh-1 double mutants, thus proving the feasibility of future suppressor screens.
These efforts should provide an important complement to current attempts in man and mouse to understand the pathophysiological mechanisms that lead to muscular dystrophy when dystrophin or other members of the dystrophin glycoprotein complex are defective. Human homologs of proteins identified in a C. elegans suppressor screen might be candidates for gene therapy approaches for Duchenne muscular dystrophy. While numerous labs are attempting to develop gene replacement therapy for Duchenne muscular dystrophy, there remain many obstacles [17] . For example, the dystrophin gene and its protein product are enormous, and difficult to deliver via viral shuttle vectors. Also, there are concerns that dystrophin might elicit an immune response when administered to patients, most of whose mutations are nulls. The direct delivery, or upregulated synthesis, of another gene product whose overexpression might suppress the dystrophic phenotype could prove to be an elegant method of therapy. Several labs are currently exploring the ability to upregulate the dystrophin homologue utrophin by administering small molecules that might regulate utrophin gene expression [18] .
Another approach to therapy, spurred by the genome project, involves a detailed analysis of globally misregulated gene expression in various forms of muscular dystrophy. This approach might identify essential members of pathways that are directly or indirectly affected by misexpression of dystrophin. Although this is enormously challenging, even with microchip technology, the relative simplicity of C. elegans muscle biology offers a facile method to streamline such a search. The worm system also offers the potential for rapid testing of experimental drugs or genes before embarking on long-term and expensive experiments in mice and humans. It is perhaps fitting that study of the largest and arguably most complex gene isolated to date, dystrophin, has finally succumbed to the power and elegance of the simple worm C. elegans.
